Hydroxamic Acid Derivatives Inhibit Anthrax Lethal Factor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for anthrax infections, particularly caused by Bacillus anthracis, are ineffective in the fulminant stage due to the accumulation of bacterial toxins, leading to high mortality rates, and there is a need for new compounds that can inhibit anthrax toxins to address the bioterrorism threat posed by this pathogen.
Innovation Solution
Development of hydroxamic acid derivatives of pyridin-2-yl alkylamines, which act as inhibitors of anthrax lethal factor, a key component of the Bacillus anthracis toxin, formulated into pharmaceutical compositions for effective treatment and prophylaxis of anthrax poisoning.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are administered in the symptomatic or fulminant stage of anthrax, then the treatment is ineffective due to toxin accumulation, but this leads to high mortality rates
Solution Approach 1:
The patent introduces hydroxamic acid derivatives as intermediary substances that specifically bind to and inhibit anthrax lethal factor (LF). These compounds act as mediators between the toxic LF and the host system, preventing LF from cleaving MAPKK enzymes. The hydroxamic acid group forms a stable complex with the zinc ion in LF's active site, effectively neutralizing the toxin's harmful effects without requiring removal of the accumulated toxin itself.
Solution Approach 2:
The patent converts the harmful accumulation of anthrax toxins into a treatable condition by introducing compounds that specifically target and neutralize the toxic effects. The hydroxamic acid derivatives transform the lethal interaction between LF and host enzymes into a benign complex, allowing the body to clear the toxins naturally while preventing further damage. This approach turns the previously fatal toxin accumulation into a manageable state through specific chemical inhibition.
2Productivity
If conventional antibiotics are used to treat anthrax infections, then bacterial growth is inhibited, but the accumulated toxins remain active and cause fulminant disease
Solution Approach 1:
The patent segments the anthrax threat into two distinct components: the bacterial organism and the toxic effects. While antibiotics address the bacterial component, the hydroxamic acid derivatives specifically target the toxic component (lethal factor). This segmentation allows simultaneous or sequential treatment of both aspects - antibiotics eliminate or control bacterial growth while LF inhibitors neutralize the already-produced toxins, providing comprehensive protection against both sources of harm.
3Adaptability or versatility
If no specific antidote is available for anthrax toxin, then the full force of the toxin acts on the host, but this results in cardiovascular collapse and death
Solution Approach 1:
The patent introduces hydroxamic acid derivatives as intermediary substances that specifically bind to and inhibit anthrax lethal factor (LF). These compounds act as mediators between the toxic LF and the host system, preventing LF from cleaving MAPKK enzymes. The hydroxamic acid group forms a stable complex with the zinc ion in LF's active site, effectively neutralizing the toxin's harmful effects without requiring removal of the accumulated toxin itself.
Data Source
AI summary
Compounds of formula I are provided: wherein X is NH, or CH2, Y is a single bond, or -CHR5-, R1 is H, C1-C4 alkyl, or C1-C4 hydroxyalkyl, R2 and R2' are each independently H, C1-C4 alkyl, or C1-C4 hydroxyalkyl, each R3 is independently H, halo, -CF3, C1-C4 alkyl, or C1-C4 alkoxy, C3 perhaloalkyl, each R4 is independently H, halo, or C1-C4 alkyl, R5 is C1-C4 alkoxy, r is integer from 0 to 3; and p is integer from 0 to 3.